Expert Interview

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Reata's SKYCLARYS (omaveloxolone) post FDA approval and the potential for competing Friedrich's Ataxia therapies

Ticker(s): RETA, LRMR

Who's the expert?

Institution: Children's Hospital of Philidelphia

Attending neurologist in the Division of Neurology at Children's Hospital of Philadelphia and Director of the Friedreich's Ataxia Program.
Research focuses on NMDA & Glutamate receptors.
Maintains a dynamic program that involves clinical, translational, and basic science research efforts focused on Friedreich ataxia.

Interview Goal

This conversation will focus on the FA pipeline and the potential use of Reata's newly approved drug SKYCLARYS (omaveloxolone). We will also dig into Larimar's lead compound, CTI-1601.

Are You Interested In These Questions?

Yes! Sign me up for FREE
so I can learn more Yes.
LOGIN!

Click Here to Access
This Project

Slingshot Insights Explained

JOIN FOR FREE TODAY

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

Click Here to Access
This Project

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.